Other OTC - Delayed Quote USD

Kiromic BioPharma, Inc. (KRBP)

2.6000 +0.1000 (+4.00%)
At close: April 19 at 10:22 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Pietro Bersani CPA, J.D. CEO & Director 891.69k -- 1968
Mr. Brian Hungerford Chief Financial Officer 160.69k -- 1976
Dr. Leonardo Mirandola Ph.D. Chief Scientific Officer & Interim COO 383.32k -- 1982
Dr. Scott Dahlbeck M.D., Pharm.D., PharmD Chief of Staff 359.08k -- 1962

Kiromic BioPharma, Inc.

7707 Fannin Street
Suite 200
Houston, TX 77054
United States
832 968 4888 https://kiromic.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
35

Description

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Corporate Governance

Kiromic BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Kiromic BioPharma, Inc. Earnings Call

Related Tickers

PHIO Phio Pharmaceuticals Corp.
0.6399
+0.77%
 
BPTS Biophytis S.A.
0.2901
-7.90%
 
TNGX Tango Therapeutics, Inc.
7.31
-0.81%
 
LIXT Lixte Biotechnology Holdings, Inc.
3.4650
+1.61%
 
OTLC Oncotelic Therapeutics, Inc.
0.0394
-6.19%
 
ARDS Aridis Pharmaceuticals, Inc.
0.0600
-2.48%
 
VRPX Virpax Pharmaceuticals, Inc.
3.6801
-5.88%
 
BLPH Bellerophon Therapeutics, Inc.
0.0544
-4.73%
 
HMTXF Hemostemix Inc.
0.0371
0.00%
 
ZURAW Zura Bio Limited
0.3500
-7.87%